🇪🇺 CD14152 Dose A in European Union

EMA authorised CD14152 Dose A on 12 February 2025

Marketing authorisation

EMA — authorised 12 February 2025

  • Application: EMEA/H/C/006149
  • Marketing authorisation holder: Galderma International
  • Local brand name: Nemluvio
  • Indication: Atopic dermatitis (AD) Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy. Prurigo nodularis (PN) Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
  • Status: approved

The European Medicines Agency (EMA) granted marketing authorisation for Nemluvio (CD14152 Dose A) on 12 February 2025. Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy. Additionally, it is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. The marketing authorisation holder is Galderma International.

Read official source →

CD14152 Dose A in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is CD14152 Dose A approved in European Union?

Yes. EMA authorised it on 12 February 2025.

Who is the marketing authorisation holder for CD14152 Dose A in European Union?

Galderma International holds the EU marketing authorisation.